These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 26014205)

  • 21. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
    Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
    Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
    Akkas BE; Vural GU
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study.
    Hallermann C; Niermann C; Fischer RJ; Schulze HJ
    Acta Derm Venereol; 2011 Sep; 91(5):521-5. PubMed ID: 21547335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.
    Pham-Ledard A; Beylot-Barry M; Barbe C; Leduc M; Petrella T; Vergier B; Martinez F; Cappellen D; Merlio JP; Grange F
    JAMA Dermatol; 2014 Nov; 150(11):1173-9. PubMed ID: 25055137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index.
    Kuusisto ME; Haapasaari KM; Turpeenniemi-Hujanen T; Jantunen E; Soini Y; Peroja P; Bloigu R; Karihtala P; Kuittinen O
    J Clin Pathol; 2015 Jul; 68(7):552-6. PubMed ID: 25935550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification.
    Suárez AL; Pulitzer M; Horwitz S; Moskowitz A; Querfeld C; Myskowski PL
    J Am Acad Dermatol; 2013 Sep; 69(3):329.e1-13; quiz 341-2. PubMed ID: 23957984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.
    Yhim HY; Kang HJ; Choi YH; Kim SJ; Kim WS; Chae YS; Kim JS; Choi CW; Oh SY; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Lee JJ; Sung HJ; Kim HJ; Lee DH; Suh C; Kwak JY
    BMC Cancer; 2010 Jun; 10():321. PubMed ID: 20569446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conjunctival Lymphoma--An International Multicenter Retrospective Study.
    Kirkegaard MM; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Toft PB; Vemuganti GK; Thuro BA; Curtin J; Heegaard S
    JAMA Ophthalmol; 2016 Apr; 134(4):406-14. PubMed ID: 26891973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
    Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
    Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Nodal versus extranodal diffuse large B-cell lymphoma: comparison of clinicopathologic features, immunophenotype and prognosis].
    Lu JB; Li XQ; Zhang PH; Zhou XY; Zhang TM; Li XM; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):470-3. PubMed ID: 17845761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management.
    Wilcox RA
    Am J Hematol; 2015 Jan; 90(1):73-6. PubMed ID: 25535037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines.
    Pedretti S; Urpis M; Leali C; Borghetti P; Baushi L; Sala R; Tucci A; Greco D; Pasinetti N; Triggiani L; Rossi G; Calzavara-Pinton P; Magrini SM; Buglione M
    Tumori; 2018 Oct; 104(5):394-400. PubMed ID: 28218382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
    Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
    JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study).
    Messina C; Ferreri AJ; Govi S; Bruno-Ventre M; Gracia Medina EA; Porter D; Radford J; Heo DS; Park HY; Pro B; Jayamohan J; Visco C; Scarfò L; Zucca E; Gospodarowicz M; Christie D;
    Br J Haematol; 2014 Mar; 164(6):834-40. PubMed ID: 24383942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
    Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
    Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secondary cutaneous lymphoma: comparative clinical features and survival outcome analysis of 106 cases according to lymphoma cell lineage.
    Lee WJ; Won KH; Won CH; Chang SE; Choi JH; Moon KC; Park CS; Huh J; Suh C; Lee MW
    Br J Dermatol; 2015 Jul; 173(1):134-45. PubMed ID: 25556641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.